| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
25048 |
| Drug |
Givinostat |
| Brand |
Duvyzat® |
| Indication |
Givinostat (Duvyzat®) is indicated for the treatment of Duchenne Muscular Dystrophy in ambulant patients, aged 6 years and older, and with concomitant corticosteroid treatment. |
| Rapid review commissioned |
05/08/2025 |
| Rapid review completed |
14/08/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of givinostat compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
26/08/2025 |
| Pre-submission consultation with Applicant |
30/09/2025 |
